Project Grant R01CA287524
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$341K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
New Orleans, LA 70112, USA
Similar Awards
This $151,000 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to identify essential biomarkers and genes involved in the formation and lifecycle of polyploid cancer cells in high-grade serous ovarian carcinoma (HGSOC). The project aims to (1) define the critical genes and transition stages required for polyploid cancer cell formation and (2) determine the expression of putative markers of polyploid cancer...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $942,442 in funding to the Dana-Farber Cancer Institute, Inc. over the period of September 1, 2024 to August 31, 2031. The goal of this research is to identify the mechanisms driving rapid evolution of cancer genomes, particularly through processes like chromothripsis and chromoplexy. The project will leverage single-cell genomics methods developed by the...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $408,913 to the University of California Irvine from August 2024 to July 2029. The funding supports research to investigate the mechanisms by which genes encoding ribosomal proteins are used as sensors for detecting altered cellular chromosome content, with a focus on the role of cell competition in eliminating aneuploid cells that have abnormal chromosome numbers. This...
This National Cancer Institute (NCI) Project Grant award, provided under the Cancer Cause and Prevention Research program (CFDA 93.393), supports a research project titled "Evaluation of a Triple Negative Matrix Signature in Tumor Progression and Resistance" at Tulane University. The $214,583 award, spanning from April 1, 2025 to March 31, 2027, aims to 1) evaluate the role of the extracellular matrix (ECM) in triple-negative breast cancer (TNBC) tumorigenesis and metastasis, and 2)...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports ongoing investigations by the Calvi Lab at Indiana University into the regulation of cell cycle and genome integrity using Drosophila melanogaster as a model system. The $1,467,801 award, effective from July 2024 through May 2029, aims to further define the variations in cell cycle and checkpoints during development and their...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to investigate the biochemical mechanisms by which human DNA topoisomerase enzymes can induce genome instability and how this may contribute to cancer development. The $160,330 award to the University of Illinois is for a 3-year period from January 2025 to December 2027. The project will utilize mutant forms of the topoisomerase enzymes to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $544,658 to New York University School of Medicine to conduct research on understanding the regulation of pyrimidine metabolism and its impact on cancer cell function and anti-tumor immunity. The research aims to:
Determine how pyrimidine overflow and disruption of the p53-dependent ribosome biogenesis checkpoint differentially affect cancer cells versus anti-cancer immune...
The federal Project Grant award of $393,943 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research aimed at defining the cellular and biochemical mechanisms that can be exploited to improve the efficacy and toxicity profile of poly (ADP-ribose) polymerase inhibitors (PARPi) for BRCA-mutant cancers. The primary award recipient, Washington University, will lead investigations into how the loss of the nucleosome sliding...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $544,478 to The University of Texas Southwestern Medical Center to conduct research on the metabolic pathways involved in purine nucleotide synthesis in cancer. The researchers will use stable isotope infusions and metabolomics to determine the relative contributions of the de novo synthesis and salvage pathways to maintaining purine nucleotide pools in tumors. They will investigate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) provides $158,020 to the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair mechanisms in the persistence of cancer cells and the development of acquired drug resistance. The research aims to:
Examine persistence and mutagenic DNA repair in BRCA1/2-mutant cancer cells treated with PARP inhibitors.
Investigate mechanisms of mutagenic...